These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35638299)

  • 1. An overview on small molecules acting as broad-spectrum agents for yellow fever infection.
    Desantis J; Felicetti T; Cannalire R
    Expert Opin Drug Discov; 2022 Jul; 17(7):755-773. PubMed ID: 35638299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
    Doyle MP; Genualdi JR; Bailey AL; Kose N; Gainza C; Rodriguez J; Reeder KM; Nelson CA; Jethva PN; Sutton RE; Bombardi RG; Gross ML; Julander JG; Fremont DH; Diamond MS; Crowe JE
    mBio; 2022 Jun; 13(3):e0051222. PubMed ID: 35420472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure.
    Mendes ÉA; Pilger DRB; Santos Nastri ACS; Malta FM; Pascoalino BDS; Carneiro D'Albuquerque LA; Balan A; Freitas LHG; Durigon EL; Carrilho FJ; Rebello Pinho JR
    Ann Hepatol; 2019; 18(6):816-824. PubMed ID: 31594756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus.
    Gao Z; Zhang L; Ma J; Jurado A; Hong SH; Guo JT; Rice CM; MacDonald MR; Chang J
    Antiviral Res; 2020 Oct; 182():104907. PubMed ID: 32798604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
    Kleinert RDV; Montoya-Diaz E; Khera T; Welsch K; Tegtmeyer B; Hoehl S; Ciesek S; Brown RJP
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31627415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.
    Thibodeaux BA; Garbino NC; Liss NM; Piper J; Schlesinger JJ; Blair CD; Roehrig JT
    Antiviral Res; 2012 Apr; 94(1):1-8. PubMed ID: 22366350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiratricol inhibits yellow fever virus replication through targeting viral RNA-dependent RNA polymerase of NS5.
    Ren H; Wang J; Tang H; Qian X; Xia B; Luo Z; Xu Z; Qi Z; Zhao P
    Antiviral Res; 2023 Nov; 219():105737. PubMed ID: 37879570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D.
    Li D; Ye JL; Liu ZY
    Virol Sin; 2021 Dec; 36(6):1456-1464. PubMed ID: 34342842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus Tropism.
    Miorin L; Laurent-Rolle M; Pisanelli G; Co PH; Albrecht RA; García-Sastre A; Morrison J
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31043530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New avenues for therapeutic discovery against West Nile virus.
    Sinigaglia A; Peta E; Riccetti S; Barzon L
    Expert Opin Drug Discov; 2020 Mar; 15(3):333-348. PubMed ID: 32017639
    [No Abstract]   [Full Text] [Related]  

  • 14. Establishment of Vero cell lines persistently harboring a yellow fever virus 17D subgenomic replicon.
    Saito K; Shimasaki K; Fukasawa M; Suzuki R; Okemoto-Nakamura Y; Katoh K; Takasaki T; Hanada K
    Virus Res; 2022 Dec; 322():198935. PubMed ID: 36152929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The eukaryotic translation initiation factor 3 subunit L protein interacts with Flavivirus NS5 and may modulate yellow fever virus replication.
    Morais ATs; Terzian AC; Duarte DV; Bronzoni RV; Madrid MC; Gavioli AF; Gil LH; Oliveira AG; Zanelli CF; Valentini SR; Rahal P; Nogueira ML
    Virol J; 2013 Jun; 10():205. PubMed ID: 23800076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.
    Zandi K; Amblard F; Amichai S; Bassit L; Tao S; Jiang Y; Zhou L; Ollinger Russell O; Mengshetti S; Schinazi RF
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.
    Douam F; Ploss A
    Trends Microbiol; 2018 Nov; 26(11):913-928. PubMed ID: 29933925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3',5'Di-O-trityluridine inhibits in vitro flavivirus replication.
    De Burghgraeve T; Selisko B; Kaptein S; Chatelain G; Leyssen P; Debing Y; Jacobs M; Van Aerschot A; Canard B; Neyts J
    Antiviral Res; 2013 May; 98(2):242-7. PubMed ID: 23470860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees.
    Mateus J; Grifoni A; Voic H; Angelo MA; Phillips E; Mallal S; Sidney J; Sette A; Weiskopf D
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33198381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
    de Freitas CS; Higa LM; Sacramento CQ; Ferreira AC; Reis PA; Delvecchio R; Monteiro FL; Barbosa-Lima G; James Westgarth H; Vieira YR; Mattos M; Rocha N; Hoelz LVB; Leme RPP; Bastos MM; Rodrigues GOL; Lopes CEM; Queiroz-Junior CM; Lima CX; Costa VV; Teixeira MM; Bozza FA; Bozza PT; Boechat N; Tanuri A; Souza TML
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007072. PubMed ID: 30699122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.